Morgan Stanley provided research notes and an Overweight rating on Gilead Sciences stock on September 20, 2026.
1 report, 1 independent
Updated Sep 20
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Morgan Stanley provided research notes and an Overweight rating on Gilead Sciences stock on September 20, 2026.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Morgan Stanley
U.S. investment bank
-
Gilead Sciences
American company
- Required regulatory filings regarding institutional holdings were made by Gilead Sciences, Inc. with the Securities and Exchange Commission on June 11, 2026.
- A pilot program is underway involving the federal government, Benue State, and Gilead Sciences, with the state participating in the drug supply management.
Related events
- Morgan Stanley analyst provides Overweight rating for SpaceX.
- Barclays reiterated an overweight rating on the stock of Brighthouse Financial.
- Morgan Stanley lowered its rating for CAE Inc from equal weight to underweight on August 27, 2026.
- Morgan Stanley downgraded Smith & Nephew's stock rating from overweight to equal weight on September 3, 2026.
- Morgan Stanley gave Micron Technology an overweight rating and included it in a list of major stocks.